A Randomised, Double-Blind, Placebo-Controlled Study of a Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) of a FimH Antagonist, EB8018, in Healthy Volunteers.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled Study of a Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) of a FimH Antagonist, EB8018, in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs EB 8018 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; First in man
  • Sponsors Enterome
  • Most Recent Events

    • 27 Oct 2017 According to an Enterome media release, results from this trial will be presented at an upcoming medical congress.
    • 27 Oct 2017 Status changed from recruiting to completed according to an Enterome media release.
    • 05 Jan 2017 According to an Enterome media release, the company anticipates to report the results from this study later in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top